Navigation Links
Echo Therapeutics Achieves ISO 13485 Certification
Date:3/15/2013

PHILADELPHIA, March 15, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced that it has been granted International Standards Organization (ISO) 13485:2003 certification of its quality management system, an internationally recognized quality standard for medical devices.

(Logo: http://photos.prnewswire.com/prnh/20120801/NE50071LOGO )

ISO 13485:2003 is an internationally recognized standard that prescribes consistent processes for the development, design and manufacturing of medical devices.  Certification to the ISO 13485 standard represents an important step toward attaining European CE Mark approval for the Company's break-through technology.

"This achievement demonstrates Echo's continued commitment to meeting and exceeding the high standards required of medical device companies selling into Europe," said Stephen Perez , Echo's Vice President of Quality Assurance. "We believe that receiving ISO 13485 certification is a significant accomplishment and an important milestone as we approach the European pivotal trial and commercialization of our Symphony CGM System."

About Echo Therapeutics
Echo Therapeutics is developing the Symphony CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system.  Our target is patients who could benefit from glucose monitoring in the hospital setting, including critical care.  Significant opportunity also exists for patients with diabetes to use Symphony in the outpatient setting.  Echo is also developing its needle-free skin preparation component of Symphony, the Prelude® SkinPrep System, as a platform technology to enhance drug delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the safety and efficacy of Echo's Symphony CGM System, the failure of future development and preliminary marketing efforts related to Echo's Symphony CGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony CGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony CGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2011, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:
Christine H. Olimpio                                         
Director, Investor Relations and Corporate Communications
(215) 717-4104 
colimpio@echotx.com                                       

Connect With Us:
- Visit our website at www.echotx.com 
- Follow us on Twitter at www.twitter.com/echotx 
- Join us on Facebook at www.facebook.com/echotx


'/>"/>
SOURCE Echo Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
2. Echo Therapeutics Appoints Robert Doman to Board of Directors
3. Autoinjectors to 2018 Devices, Therapeutics, Markets, Strategies and Prospect
4. ADVENTRX Completes Name Change To "Mast Therapeutics, Inc."; New Ticker Symbol: "MSTX"
5. Cell Therapeutics to Present at the ROTH Capital Partners 25th Annual Growth Stock Conference
6. PTC Therapeutics Closes $60 Million Private Financing
7. Orexigen Therapeutics to Host Full Year and Fourth Quarter 2012 Financial Results Conference Call and Webcast
8. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
9. Todays Research on PDL BioPharma, Dendreon, Medivation, ACADIA Pharma, and Cell Therapeutics
10. Halozyme Therapeutics to Present at the Barclays 2013 Global Healthcare Conference
11. Relmada Therapeutics Announces LevoCap ER Development Progress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... LONDON , February 20, 2017 Acute, Chronic ... is expected to grow at a CAGR of 7% from 2016-2021 and ... a CAGR of 6% from 2016 to 2027. The market is estimated ... ... Read on to discover how you can exploit the future business ...
(Date:2/19/2017)... , February 18, 2017 ... agreement to purchase a Medical Delivery Service with the ... cannabis transactions between qualified patients and caregivers. The delivery ... , located in the Coachella Valley, California ... Greater Los Angeles area to the West, ...
(Date:2/18/2017)... , Feb. 17, 2017 Research and Markets ... Report" report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , Latin America ... the period 2015 through 2022. Also, a six-year historic analysis is provided ...
Breaking Medicine Technology:
(Date:2/20/2017)... Boston, MA and Orlando, FL (PRWEB) , ... ... ... Strohbusch, Orbita PR Director, beth[at]orbitahealth[dot]com, +1 (414) 213-8818 , Orbita, Inc., a leading ... ™, a complete software-as-a-service solution for increasing patient engagement and optimizing care journey ...
(Date:2/20/2017)... Plano, Texas (PRWEB) , ... February 20, 2017 ... ... vital signs technology, welcomes you to stop by for a visit this week ... IT professionals, clinicians and executives from around the globe. Sensogram will be featured ...
(Date:2/20/2017)... (PRWEB) , ... February 20, 2017 , ... Chuck E. ... Sensory Sensitive Sundays, a joint event at Chuck E. Cheese’s locations throughout New England, ... other special needs, the opportunity to experience the fun of visiting Chuck E. Cheese’s ...
(Date:2/19/2017)... ... , ... ProBrand Glitch is a set of 30 glitch distortion logo reveals made exclusively for ... logo with a glitch reveal in just a few clicks of a mouse. Customizable glitch ... each preset. Use these presets to add a uniquely animated logo to any photos or ...
(Date:2/18/2017)... ... February 17, 2017 , ... Butler Mobility invited Ken ... Stairlift and other Butler products. Ken was impressed with the safety and reliability ... endorse the product on his show. This endorsement by Ken Matthews can be ...
Breaking Medicine News(10 mins):